Breaking news on erectile dysfunction premature ejaculation
Suspended Sentence For The Illegal Sale And Supply Of Sex Drugs published
Thu, 09 Sep 2010 03:00:00 PDT
A 61-year-old man from Sutton Coldfield, West Midlands received a nine month prison sentence suspended for two years last Monday, with supervision for one year, at Birmingham Crown Court for the illegal sale and supply of erectile dysfunction medicines...
LEVITRA 10mg Orodispersible Tablet For The Treatment Of Erectile Dysfunction Approved In Europe published
Tue, 07 Sep 2010 00:00:00 PDT
The European Commission has approved a new formulation of Levitra® (vardenafil HCI). Levitra 10mg orodispersible tablet will be the first erectile dysfunction (ED) medication available in this novel and convenient formulation...
Many Older Adults With Diabetes Are Sexually Active But Have Problems published
Mon, 30 Aug 2010 10:00:00 PDT
New research from the University of Chicago found that many middle-aged and older Americans with diabetes are sexually active but more likely to experience sexual problems compared with counterparts without diabetes...
Palatin Technologies, Inc. Announces Positive Safety Results In Subcutaneous Bremelanotide Trial In Men published
Wed, 18 Aug 2010 02:00:00 PDT
Palatin Technologies, Inc. (NYSE Amex: PTN) announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD)...
Novacare LLC Conducts Voluntary Nationwide Recall Of Products Found To Contain Undeclared Drug Ingredient published
Wed, 11 Aug 2010 07:00:00 PDT
Novacare LLC has announced that it is conducting a voluntary nationwide recall of products sold under the following names: Stiff Nights, Aziffa, Size Matters, Erex, Mojo, Hard Drive, Eyeful, Red Magic, Straight Up, Zotrex, Monster Excyte, WOW, Xaitrex, Verect, Prolatis, Xytamax, Maxyte, Libidinal, OMG, OMG45, and Zilex (with Golden Spear)...
EZVille, Ltd. Issues A Voluntary Nationwide Recall Of Revivexxx® Extra Strength Found To Contain An Undeclared Drug Ingredient published
Wed, 11 Aug 2010 07:00:00 PDT
EZVille, Ltd. of Ronkonkoma, NY, has been informed by the US Food and Drug Administration (FDA) that FDA lab analysis of Revivexxx® Extra Strength distributed by the company was found to contain undeclared tadalafil. Tadalafil is an FDA-approved drug for the treatment of male Erectile Dysfunction (ED), making Revivexxx® Extra Strength an unapproved drug...
Laser May Reduce Prostate Surgery's Long-Term Erectile Dysfunction published
Fri, 06 Aug 2010 03:00:00 PDT
One of the challenges of prostate cancer surgery is removing the cancer-affected gland without side effects. The procedure is estimated to cause long-term sexual dysfunction in half of men...
Peyronie's Disease Following Radical Prostatectomy: Incidence And Predictors published
Tue, 03 Aug 2010 00:00:00 PDT
UroToday.com - Peyronie's disease (PD) occurs more frequently following radical prostatectomy (RP) than it does among men in the general population, according to a report by Dr. Raanan Tal and colleagues in the Journal of Sexual Medicine. In the general population, the incidence of PD is reported to be 3.2-8.9%...
The Future Is Today: Emerging Drugs For The Treatment Of Erectile Dysfunction published
Tue, 03 Aug 2010 00:00:00 PDT
UroToday.com - Erectile Dysfunction (ED) is the most common male sexual dysfunction presented for treatment, and the most thoroughly studied sexual dysfunction in men. In the late 20th century, important discoveries were made regarding both the physiologic processes of penile erection and the pathophysiology of ED...
Federal Agents Seize FastSize Extenders And FastSize EQM Erectile Quality Monitors published
Wed, 28 Jul 2010 03:00:00 PDT
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized $346,954.43 worth of FastSize Extender devices and FastSize EQM Erectile Quality Monitor devices, as well as component parts used in the manufacture of the FastSize Extender. The FastSize Extender and the FastSize EQM Erectile Quality Monitor are manufactured and distributed by FastSize, LLC of Aliso Viejo, Calif...
Dangers Of Untreated Erectile Dysfunction published
Wed, 21 Jul 2010 02:00:00 PDT
Research carried out by a visiting professor at the University of Hertfordshire has found that up to six million European men fail to seek help for Erectile Dysfunction (ED) which could result in underlying cardiovascular disease going undetected...
Increased Risk Of Cardiovascular Problems In Depressed Men With Erectile Dysfunction published
Wed, 14 Jul 2010 03:00:00 PDT
A new study in the Journal of Sexual Medicine found that the presence of depressive symptoms in men with erectile dysfunction constitutes a risk factor for a major cardiovascular event. Erectile dysfunction and depressive mood are often associated, and both are associated with an increased risk of cardiovascular disease and death...
Furiex Pharmaceuticals Announces Issuance Of U.S. Patent For Dapoxetine Method Of Treatment published
Wed, 07 Jul 2010 01:00:00 PDT
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced that the United States Patent and Trademark Office issued a patent on May 18, 2010, for the method for treatment of premature ejaculation using dapoxetine. Furiex developed dapoxetine in collaboration with Alza Corporation and its affiliates. U.S. Patent No...
Study Finds Higher STD Rates Among Users Of Erectile Dysfunction Drugs published
Tue, 06 Jul 2010 02:00:00 PDT
Physicians who prescribe erectile dysfunction drugs for their male patients should be sure to discuss the importance of safer sex practices, even with older patients: that is an important implication of a report in the July 6 issue of Annals of Internal Medicine. The analysis of insurance records of more than 1.4 million U.S...
NexMed Announces First Patent Allowance For Vitaros(R) In Japan published
Sun, 27 Jun 2010 01:00:00 PDT
NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of product candidates based on the NexACT® technology, announced that the Japanese Patent Office has issued the Decision to Grant a Patent for NexMed's patent application entitled, "Prostaglandin Compositions for the Treatment of Male Erectile Dysfunction...
Erectile Dyfunction - Marker For Heart Attack published
Mon, 21 Jun 2010 02:00:00 PDT
Seven out of 10 men admitted to hospital for a heart attack (acute ST segment elevation myocardial infarction (STEMI)) had erectile dysfunction (ED) in the six months prior to their admission according to new data presented at the World Congress of Cardiology (WCC) Scientific Sessions in Beijing, China...
'Sonic Hedgehog' Helps Regenerate Critical Nerve That Runs Along Prostate, Could Heal Erectile Dysfunction After Surgery published
Thu, 10 Jun 2010 00:00:00 PDT
After men have surgery to remove a cancerous prostate gland, up to 80 percent of them will lose the ability to have an erection because of damage to a critical nerve that runs along the prostate. New research from Northwestern University Feinberg School of Medicine shows the damaged nerve can be regenerated more quickly with a protein called sonic hedgehog delivered via a nanofiber gel...
Testosterone To Treat 'Male Menopause' Questionable published
Thu, 03 Jun 2010 09:00:00 PDT
Given that it is not clear whether male menopause actually exists, and inconclusive evidence on testosterone's effectiveness in treating it, an article in today's Drug Therapeutics Bulletin (DTB), a BMJ (British Medical Journal) journal, says that the use of synthetic testosterone is questionable...
Physician-Scientists Present At 2010 American Urological Meeting published
Thu, 03 Jun 2010 02:00:00 PDT
Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center presented their latest research findings at the American Urological Association's Annual Meeting in San Francisco, May 29 to June 3. Dr. Steven Kaplan, a urologist and professor of urology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and Dr...
Positive Results From Phase 3 Study Of Avanafil In Erectile Dysfunction Presented At AUA Annual Meeting published
Wed, 02 Jun 2010 02:00:00 PDT
VIVUS, Inc. (Nasdaq: VVUS) announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting...
Link Established Between Erectile Dysfunction And Calcified Coronary Arteries published
Wed, 02 Jun 2010 01:00:00 PDT
In the largest study to date evaluating erectile dysfunction (ED) and coronary artery calcification, researchers at Mount Sinai School of Medicine have determined that men with ED are at a significantly increased risk of high coronary artery calcification scores (CACS), a known predictor of future cardiovascular events...
Pivotal Data For The Investigational Treatment PSD502 For Primary Premature Ejaculation In The U.S. To Be Presented At Meeting published
Tue, 01 Jun 2010 17:00:00 PDT
Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco...
Counterfeit ED Drugs Pose Fatal Health Risks published
Tue, 01 Jun 2010 04:00:00 PDT
Counterfeit drugs for erectile dysfunction (ED) can contain toxic materials, too much active ingredient or no active ingredient at all and pose serious health risks, according to research presented at the 105th Annual Scientific Meeting of the American Urological Association (AUA)...
Pivotal Data For The Investigational Treatment PSD502 For Primary Premature Ejaculation published
Tue, 01 Jun 2010 03:00:00 PDT
Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco...
Phase 3 Data On VIVUS' Avanafil For Erectile Dysfunction To Be Featured At The AUA 2010 Annual Meeting published
Sat, 29 May 2010 01:00:00 PDT
VIVUS, Inc. (Nasdaq: VVUS) announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 (PDE5) inhibitor therapy being investigated for the treatment of erectile dysfunction (ED), will be presented next Tuesday at the American Urological Association (AUA) 2010 Annual Meeting in San Francisco, California. Irwin Goldstein, M.D...
)
|
|
